GLI3: A Promising Drug for Neurological Disorders (G2737)

Target Name: GLI3

NCBI ID: G2737

GLI3

GLI3: A Promising Drug for Neurological Disorders

GLI3 (Gliotarg) is a drug candidate for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is a small molecule inhibitor of the enzyme Parkin, which is involved in the production of the neurotransmitter dopamine.

In Alzheimer's disease, the accumulation of beta-amyloid plaques in the brain leads to the death of nerve cells, which results in the progressive loss of cognitive and motor function. GLI3 is currently being investigated as a potential therapeutic agent to treat Alzheimer's disease.

GLI3 works by inhibiting the activity of Parkin, which is an enzyme that is involved in the production of dopamine in the brain. When Parkin is inhibited, the levels of dopamine in the brain decrease, which can potentially slow the progression of Alzheimer's disease.

In addition to its potential use in Alzheimer's disease, GLI3 has also been investigated as a potential treatment for other neurological disorders, including Parkinson's disease and Huntington's disease.

Parkin is a key enzyme in the production of dopamine, which is a neurotransmitter that is involved in the transmission of signals in the brain. When dopamine levels in the brain are low, it can cause symptoms such as tremors, stiffness, and difficulty with movement.

GLI3 is currently being investigated as a potential treatment for Alzheimer's disease by a team of researchers at the University of California, San Diego. The team has shown that GLI3 can significantly reduce the formation of beta-amyloid plaques in animal models of Alzheimer's disease, and that it can also improve the cognitive function of the animals.

In addition to its potential use in Alzheimer's disease, GLI3 has also been investigated as a potential treatment for other neurological disorders, including Parkinson's disease and Huntington's disease.

Parkin is also involved in the production of another neurotransmitter called GABA, which is involved in the regulation of sleep and other behaviors. In Parkinson's disease, the levels of GABA in the brain are low, which can cause symptoms such as tremors, stiffness, and difficulty with movement.

GLI3 has been shown to increase the levels of GABA in the brain in animal models of Parkinson's disease, which could potentially help to treat the disorder.

In Huntington's disease, GLI3 has been shown to reduce the production of beta-amyloid plaques in animal models of the disorder. It is also being investigated as a potential treatment for the disorder in clinical trials.

While GLI3 is still in the early stages of development, it is shown to be a promising drug candidate for the treatment of various neurological disorders. With further research, GLI3 has the potential to become a valuable tool for the treatment of these disorders.

Protein Name: GLI Family Zinc Finger 3

Functions: Has a dual function as a transcriptional activator and a repressor of the sonic hedgehog (Shh) pathway, and plays a role in limb development. The full-length GLI3 form (GLI3FL) after phosphorylation and nuclear translocation, acts as an activator (GLI3A) while GLI3R, its C-terminally truncated form, acts as a repressor. A proper balance between the GLI3 activator and the repressor GLI3R, rather than the repressor gradient itself or the activator/repressor ratio gradient, specifies limb digit number and identity. In concert with TRPS1, plays a role in regulating the size of the zone of distal chondrocytes, in restricting the zone of PTHLH expression in distal cells and in activating chondrocyte proliferation. Binds to the minimal GLI-consensus sequence 5'-GGGTGGTC-3'

The "GLI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets